DMK Pharmaceuticals Corporation
CY3B
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -22.23M | -25.24M | -25.07M | -26.48M | -31.92M |
| Total Depreciation and Amortization | 636.00K | 967.80K | 1.25M | 1.48M | 1.48M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.08M | 7.24M | 2.05M | 400.70K | 342.80K |
| Change in Net Operating Assets | 6.17M | 3.93M | 1.33M | -1.28M | -905.20K |
| Cash from Operations | -9.35M | -13.11M | -20.43M | -25.87M | -31.01M |
| Capital Expenditure | -91.50K | -299.30K | -653.50K | -680.40K | -816.10K |
| Sale of Property, Plant, and Equipment | 4.09M | 4.09M | 4.09M | 4.09M | 1.41M |
| Cash Acquisitions | 136.10K | 136.10K | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.23M | -2.01M | -644.40K | 73.40K | 3.90M |
| Cash from Investing | 2.90M | 1.91M | 2.79M | 3.48M | 4.49M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 8.88M | 800.00 | -- | -- | 3.33M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 15.00K | 300.00K | 300.00K | 300.00K | 285.00K |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.80M | 2.71M | 2.71M | -15.00K | -3.37M |
| Cash from Financing | 10.69M | 3.01M | 3.01M | 285.00K | 242.20K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -30.10K | -52.20K | -35.90K | -35.90K | -35.90K |
| Net Change in Cash | 4.21M | -8.24M | -14.67M | -22.14M | -26.31M |